^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

SKAP2 (Src Kinase Associated Phosphoprotein 2)

i
Other names: SKAP2, Src Kinase Associated Phosphoprotein 2, SKAP-HOM, SKAP55R, RA70, SAPS, Src-Associated Adapter Protein With PH And SH3 Domains, Src Kinase-Associated Phosphoprotein, Src Family-Associated Phosphoprotein, Retinoic Acid-Induced Protein 70, Pyk2/RAFTK-Associated Protein, SKAP55 Homolog, SKAP-55HOM, SCAP2, PRAP, Src Kinase-Associated Phosphoprotein Of 55-Related Protein, Src Kinase-Associated Phosphoprotein 55-Related Protein, Fyn-Associated Phosphoprotein SKAP55 Homologue, Src Family Associated Phosphoprotein 2
4ms
MAPK3 Modulates Enhancer-Promoter Interactions of SKAP2 in Acute Myeloid Leukemia. (PubMed, Carcinogenesis)
Furthermore, deletion of enhancer regions E4 and E6 led to decreased SKAP2 expression. These findings highlight the critical role of MAPK3 in regulating CTCF-mediated chromatin interactions and suggest that targeting MAPK3-regulated chromatin remodeling could be a novel therapeutic strategy for AML.
Journal
|
SKAP2 (Src Kinase Associated Phosphoprotein 2) • MAPK3 (Mitogen-Activated Protein Kinase 3)
1year
Combined RET and MEK Inhibition as a Treatment for RET Fusion-Positive NSCLC With Acquired BRAF Fusion: A Case Report. (PubMed, JTO Clin Res Rep)
She was then treated with a combination of selpercatinib and trametinib, which led to a likely partial response, despite the combination demonstrating side effects. This case report details the first known instance of NSCLC with a RET fusion developing resistance by means of a BRAF fusion, treated with combined RET and MEK inhibition.
Journal
|
BRAF (B-raf proto-oncogene) • RET (Ret Proto-Oncogene) • CCDC6 (Coiled-Coil Domain Containing 6) • SKAP2 (Src Kinase Associated Phosphoprotein 2)
|
RET fusion • CCDC6-RET fusion • BRAF fusion • RET positive
|
Mekinist (trametinib) • Retevmo (selpercatinib)
over1year
Pleomorphic Parotid Adenoma in a Child Affected with Cri du Chat Syndrome: Clinical, Cytogenetic, and Molecular Analysis. (PubMed, Int J Mol Sci)
This is particularly also relevant in relation to the severely impaired possibility for patients with CdC to report discomfort or pain related to tumor development. Constitutional CNVs in addition to the deletion in 5p should also be extensively studied to verify if their presence in some patients could explain why, in these cases, tumors develop at an age younger than expected.
Journal
|
SKAP2 (Src Kinase Associated Phosphoprotein 2)
over1year
SKAP1 Expression in Cancer Cells Enhances Colon Tumor Growth and Impairs Cytotoxic Immunity by Promoting Neutrophil Extracellular Trap Formation via the NFATc1/CXCL8 Axis. (PubMed, Adv Sci (Weinh))
Furthermore, inhibiting SKAP1-induced NET significantly enhanced the antitumor efficiency of adoptive natural killer cell therapy in colon tumor models. In conclusion, SKAP1 significantly promotes colon cancer growth via the cancer cell/neutrophil NFATc1/CXCL8/NET axis, suggesting that SKAP1 is a potential target for colon cancer therapy.
Journal
|
CXCL8 (Chemokine (C-X-C motif) ligand 8) • SKAP2 (Src Kinase Associated Phosphoprotein 2) • NFATC1 (Nuclear Factor Of Activated T Cells 1) • SKAP1 (Src Kinase Associated Phosphoprotein 1)
almost2years
SKAP2 acts downstream of CD11b/CD18 and regulates neutrophil effector function. (PubMed, Front Immunol)
Our results suggest that SKAP2 has a dual role. It may restrict CD11b/CD18-mediated adhesion only under resting conditions, but its major contribution lies in the regulation of dynamic CD11b/CD18-mediated actin rearrangements and clustering as required for cellular effector functions of human neutrophils.
Journal
|
ICAM1 (Intercellular adhesion molecule 1) • SKAP2 (Src Kinase Associated Phosphoprotein 2) • ITGAM (Integrin, alpha M) • ITGB2 (Integrin Subunit Beta 2) • TLN1 (Talin 1)
2years
Integration of Transcriptomic Features to Improve Prognosis Prediction of Pediatric Acute Myeloid Leukemia With KMT2A Rearrangement. (PubMed, Hemasphere)
By integrating clinical characteristics, we proposed a simple-to-use prognostic scoring system with excellent discriminability, which allowed us to distinguish allogeneic hematopoietic stem cell transplantation candidates more precisely. In conclusion, pediatric KMT2A-r AML is heterogenous on transcriptomic level and the newly proposed scoring system combining clinical characteristics and transcriptomic features can be instructive in clinical routines.
Journal
|
KMT2A (Lysine Methyltransferase 2A) • SKAP2 (Src Kinase Associated Phosphoprotein 2)
|
KMT2A rearrangement • MLL rearrangement
over2years
SKAP1 Is a Novel Biomarker and Therapeutic Target for Gastric Cancer: Evidence from Expression, Functional, and Bioinformatic Analyses. (PubMed, Int J Mol Sci)
In summary, SKAP1 is overexpressed in GC, where it promotes cell proliferation, invasion and migration and is associated with poor prognosis and poor immunotherapy outcomes. SKAP1 may represent a biomarker and therapeutic target in GC and regulates cellular functions through JAK1/PI3K/AKT signaling.
Journal • IO biomarker
|
JAK1 (Janus Kinase 1) • SKAP2 (Src Kinase Associated Phosphoprotein 2)
over2years
Brain matters: unveiling the distinct contributions of region, age, and sex to glia diversity and CNS function. (PubMed, Acta Neuropathol Commun)
Across all glia, sex differences are subtle but the consistent increased expression of protein-folding genes in male donors hints at pathways that may contribute to sex differences in disease susceptibility. These findings are essential to consider for understanding selective CNS pathologies and developing tailored therapeutic strategies.
Journal
|
SKAP2 (Src Kinase Associated Phosphoprotein 2)
over3years
SNORA70E promotes the occurrence and development of ovarian cancer through pseudouridylation modification of RAP1B and alternative splicing of PARPBP. (PubMed, J Cell Mol Med)
In conclusion, SNORA70E promotes the occurrence and development of ovarian cancer through pseudouridylation modification of RAP1B and alternative splicing of PARPBP. Our results demonstrated that SNORA70E may be a new diagnostic and therapeutic target for ovarian cancer.
Journal • PARP Biomarker
|
AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • PARP1 (Poly(ADP-Ribose) Polymerase 1) • SKAP2 (Src Kinase Associated Phosphoprotein 2) • MMP9 (Matrix metallopeptidase 9) • PI3K (Phosphoinositide 3-kinases)
over3years
CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia. (PubMed, Exp Hematol Oncol)
Before the CAR T-cell therapy, the patient achieved partial remission with IA regimen and attained complete remission after reinduction therapy (decitabine and venentoclax)...Then she failed CLIA regimen combined with venetoclax and exhibited resistance to FLT3 inhibitors...In summary, the autologous CD7 CAR T-cell therapy could be considered a potential approach for AML with CD7 expression (NCT04762485).Trial registration Clinical Trials.gov, NCT04762485. Registered on February 21, 2021, prospectively registered.
Journal • CAR T-Cell Therapy • IO biomarker
|
TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • RUNX1 (RUNX Family Transcription Factor 1) • SKAP2 (Src Kinase Associated Phosphoprotein 2) • CD7 (CD7 Molecule)
|
FLT3-ITD mutation • RUNX1 mutation • TP53 deletion • CD7 expression
|
Venclexta (venetoclax) • decitabine • PA3-17
almost4years
THUMPD3-AS1 facilitates cell growth and aggressiveness by the miR-218-5p/SKAP1 axis in colorectal cancer. (PubMed, Cell Biochem Biophys)
THUMPD3-AS1 promotes CRC cell growth and aggressiveness by regulating the miR-218-5p/SKAP1 axis.
Journal
|
SKAP2 (Src Kinase Associated Phosphoprotein 2) • MIR218 (MicroRNA 218)
almost4years
SKAP2 suppresses inflammation-mediated tumorigenesis by regulating SHP-1 and SHP-2. (PubMed, Oncogene)
SHP-2 is required for efficient NF-κB activation and suppresses the TRAM/TRIF-INFβ pathway; therefore, SKAP2-mediated SHP-2 inhibition affected two signaling axes from TLR4. The present findings indicate that SKAP2 prevents excess inflammation by inhibiting the TLR4-NF-κB pathway, and it activates the TLR4-IFNβ pathway through SHP-1 and SHP-2, thereby suppressing inflammation-mediated tumorigenesis.
Journal • IO biomarker
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • SKAP2 (Src Kinase Associated Phosphoprotein 2) • IL1B (Interleukin 1, beta) • IFNB1 (Interferon Beta 1) • SIRPA (Signal Regulatory Protein Alpha)